Summary DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone E09. In preclinical studies, E09 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours (mean 123 nmol DCPIP min' mg-'), followed by colon carcinoma (mean 75 nmol minm mg-') and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min-'mg-'), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min-' mg-'), was not observed for these enzymes (CP450R, cytochrome cmin1'mg-1; Cb5R, 3.5-27.6nmolmin-'mg-'). It is anticipated that NSCLC patients are more likely to respond to E09 and other bioreductive agents, owing to the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we need to study these enzyme levels in tumour samples obtained from patients on clinical studies with bioreductive agents.
DT-diaphorase (DTD, ECI.6.99.2) is considered to be the most important enzyme for the activation of bioreductive drugs such as E09 and diaziquone (AZQ); at low pH it can also reduce mitomycin C (MMC) [Siegel et al., 1990; Walton et al., 1991; Riley and Workman, 1992; Siegel et al., 1992; Workman, 1992] . DTD is present in many mammalian tissues, where it can play a role in the biosynthesis of vitamin K (Wallin et al., 1978; Ernster, 1987) , or may act as a detoxifying enzyme, by catalysing a strict two-electron reduction (Benson et al., 1980; Ernster, 1987) . For AZQ and E09 this reduction however leads to bioactivation of reactive groups, inducing their toxic properties such as DNA damage (Siegel et al., 1990; Walton et al., 1991; 1992a) . E09, a bioreductive alkylating indoloquinone, is a structural analogue of MMC and has shown selective activity against solid tumour types, in vitro and in animal models (Oostveen and Speckamp, 1987; Hendriks et al., 1993) . Clinical phase I trials with E09 have just been finished (Schellens et al., 1994) .
Several studies have been published recently, in which a correlation was postulated between the DTD levels (both expression and activity) and the chemosensitivity to E09 under normoxic conditions (Robertson et al., 1992; Walton et al., 1992b; Plumb et al., 1994a; Smitskamp-Wilms et al., 1994) . For other reductive enzymes such as the one-electrondonating NADH cytochrome b5 reductase (Cb5R) and NADPH cytochrome P450 reductase (CP450R) no such relation with E09 sensitivity was found in more than 20 human tumour cell lines (Ross et al., 1993; Plumb et al., 1994a,c) . It has however been reported that CP45OR can reduce E09 (Bailey et al., 1994) . Under hypoxic conditions the role of DTD is less clear; it seems that in cells with low DTD other reductases play a more prominent role under low-oxygen conditions, while metabolism of E09 by DTD dominates in DTD-rich cells, in both air and hypoxia (Plumb et al., 1994a,b,c; Robertson et al., 1994) . On the other hand, Yao et al. (1994) observed a 3-to 5-fold increase in DTD and CP45OR mRNA by exposing a colon cell line to hypoxia. Apart from hypoxia, expression of DTD can also be induced by chemical inducers (Benson et al., 1980; Prochaska and Talalay, 1988) , including cytotoxic drugs or carcinogens. Several reports have mentioned higher DTD levels (both activity or mRNA) in tumour cells compared with normal tissues (Schor and Cornelisse, 1983; Schlager and Powis, 1990; Cresteil and Jaiswal, 1991) , although not for all tumour types (Schlager and Powis, 1990) .
The logical sequel to these studies would be to investigate the relation between DTD and sensitivity to bioreductive drugs in human tumour tissues. In this way it will be possible to select suitable tumours for treatment with, for example, E09, following the 'enzyme directed approach' as put forward by . Therefore, we measured DTD levels in a number of human normal (from colon, lung, liver, blood and head and neck) and neoplastic tissues (from colon, lung and head and neck) to determine whether, and if so in which tumour types, E09 would exert selectivity. The activity of two one-electron reductases, Cb5R and CP450R, was measured for comparison and because of their possible role in the activation of E09 under hypoxia (Plumb et al., 1994b,c; Robertson et al., 1994 (Peters et al., 1993 All the lung specimens were obtained from patients with non-small-cell lung cancer (NSCLC) undergoing radical resection. Four tumours were classified as squamous cell carcinoma (SCC), one as an adenocarcinoma (AD), one as combined adenosquamous (AS) and one as large cell (LC). All patients had a smoking history.
Blood was taken from a healthy volunteer. After centrifugation, the fraction with the red cells was sonicated on ice.
Sample preparation Biopsy specimens were obtained from several tumours and histologically confirmed. Adjacent normal appearing tissue was frozen separately. Normal and tumour tissues had been frozen immediately after surgery in liquid nitrogen and kept at -80°C. At the day of the enzyme assays, the still frozen tumour was cut into small pieces (with a total weight of maximum ± 100 mg) and was pulverised in a liquid nitrogencooled vessel using a microdismembrator (B Braun, Melsungen, Germany, Peters et al., 1986 , 1994) . The DTD activity in the different tissue types are depicted in Figure la , b and c. As a group DTD activity was highest in NSCLC tumours, followed by colon tumours and metastases (three liver and one lymph node) of colon tumours. Normal lung and liver tissue and squamous cell carcinoma of the head and neck contained low DTD activity (Table I ). In the sets of paired tissues obtained from three NSCLC patients, all tumours clearly had significantly elevated DTD levels (P = 0.008) compared with normal lung tissues (7-, 12-and 66-fold higher; Figure ic) . In colon mucosa, this difference was less clear. From the three paired samples, the DTD activity was three times lower in one mucosa than in the corresponding tumour (patient 7), while in the other two patients (patients 19 and 55), there was no difference in DTD activity (Figure la) . The colon tumours showed a varying range of DTD activities. In four of the primary colon tumours, DTD activity was higher than 46 nmol min-' mg-'. In the other four, in the colon cancer metastases (three liver and one lymph node) and in normal colon mucosa, intermediate levels were found (2 -31 nmol min-' mg-1), while in normal liver it was very low (4 nmol min' mg-').
This means that the metastatic tissue is more similar to the primary tumour than to the local liver tissue (Figure la) . Thirteen of the patients in the colon cancer group had received a single injection of 5FU just before the surgery. However, DTD activities in the three livers from treated patients (1', 2', 3') were not different from the three control (no 5FU) livers (patients 17, 57, 58). Similarly, other samples from untreated patients (primary tumour and mucosa) had DTD levels in the same range as that of treated patients. As a control, possible induction by 5FU or E09 was measured in two colon carcinoma cell lines. Both in SW620 and WiDr cells, no induction by these compounds was observed after 24 h exposure to IC50 concentrations (results not shown).
In the head and neck tumours we observed low to intermediate DTD levels. In these tumours the activity was much lower than in the lung and colon tumours; in addition the activity was not significantly different from normal (Mann-Whitney U-test: P = 0.4) or intermediate (P = 0.14) tissues, including normal tissue from non-cancer patients (Table 1, Figure lb) .
In normal liver, DTD activity measured as DCPIP reduction was very low (4 nmol min lmg-'). Whereas in the tumour extracts low concentrations of dicoumarol almost completely inhibited the enzyme activities (>90%) similar to cell lines, in normal liver dicoumarol inhibited only 40-50% (Figure 2) . In all tested tumours and colon mucosa these one-electron-donating enzymes were less abundant than DTD (Table II) , although it is difficult-to draw an exact parallel since substrates differ. Levels varied between 5% and 60% of that of DTD (range 3.5-27.6 nmol min' mg', median 13 nmol min' mg-'). In contrast, the liver extracts contained much higher Cb5R activity compared with that of DTD (230-470%), although the absolute activities were in the same range (7.6-23nmol min' mg-1) as in the colon tissues. Also, absolute CP45OR activities were similar among liver and other tissues (range 0.8-7.8 nmol min -' mg -). But, relative to DTD, in normal liver CP45OR activities were higher than in other tissues.
DTD could not be detected in red blood cells. Although DCPIP was being reduced at a relatively low level (5 nmol min' mg-' protein or 300 nmol min lml-' red blood cells), this reduction could not be inhibited by dicoumarol.
Similar to the DTD activity in cell lines (Smitskamp-Wilms et al., 1994) , we noticed variations in the linearity of the assay depending on the source of tissue. For some of the samples with high DTD activity (>50 nmol min' mg' or >250 nmol min-ml-'), it was necessary to use higher dilutions in order to perform measurements in the linear range. This range varied per sample but in general was in the low protein range (<60 gLg per assay) for samples with high activity (> 50 nmol min' mg-'). For tissues with an activity lower than 25 nmol min-mg-' (or < 100 nmol min' I ml-'), this range was less narrow and went up to 300 tg per assay.
Discussion
In this study we demonstrate that only in human lung tumours (NSCLC) DTD activity was significantly higher than in normal tissues. In the other tumour types investigated (colon, including some metastases, and SSC of the head and neck) this difference was not observed, whereas the reductase; _, NADPH cytochrome P450 reductase) activity in human tissues. The sample codes are the same as used in Figure  1 . SQ, squamous cell carcinoma; AS, combined adenosquamous; AD, adenocarcinoma; LC, large cell.
DTD activity in these tumours was also lower than in lung tumours.
These high levels in NSCLC samples are in agreement with the data reported by Malkinson et al. (1992); Ross et al. (1993) . Much higher DTD levels were found in NSCLC compared with small-cell lung cancer and normal lung. Generally, DTD levels in cell lines derived from NSCLC were higher than in small-cell lung cancer (SCLC) cell lines or other cell lines (Malkinson et al., 1992; Robertson et al., 1992 Robertson et al., , 1994 . These results indicate that NSCLC is more likely to be sensitive to E09 than other tumour types (Ross et al., 1993; Stratford et al., 1994) . Consequently, NSCLC is one of the diseases selected for phase II clinical trials.
Several reports mentioned that the activity of DTD is higher in tumour cells than in normal cells of the same origin (Schor and Cornelisse 1983; Schlager and Powis 1990; Cresteil and Jaiswal 1991; Malkinson et al., 1992) . This has been found in primary tumours of lung, liver, colon, breast and testis (Schlager and Powis, 1990) . However, in tumours from kidney and stomach, lower enzyme activities were found when compared with normal tissue (Schlager and Powis 1990; Eickelmann et al., 1994) . In this study, in addition to small differences between normal colon mucosa and primary colon tumours, we found that head and neck tumours showed the same activity pattern as the surrounding normal tissues. Normal tissue from the head and neck region from non-cancer patients showed the same DTD levels, indicating that the results were not influenced by their location with respect to the tumour.
Studies on regulation of expression of DTD (Prochaska and Talalay 1988; Cresteil and Jaswail 1991: Belinsky and Jaiswal 1993) indicated that DTD can be induced by cytotoxic drugs. However, our results show no difference in DTD activities between three livers from patients who had Intra-assay variation among duplicates was < 10%.
been treated with 5FU and three liver samples from untreated patients (LIV 1', 2' and 3'). Also in vitro no induction by physiologically relevant concentrations of 5FU or E09 was observed.
The very low DTD activities in human normal liver are in sharp contrast to DTD in rodent normal livers (Schlager and Powis 1990) . Differences in kinetic behaviour of isolated rat and human DTD as described by Boland et al. (1991) emphasise again that rodent models are not always appropriate models for human drug therapy.
One-electron reductase activities in tumour tissues were 2-60% compared with that of DTD, while cytochrome b5 reductase levels were always higher than those of cytochrome P450 reductase. This was in line with other studies, reporting levels varying around 20% of that of DTD (Schlager and Powis 1990; Walton et al., 1992; Hendriks et al., 1993; Ross et al., 1993) . Relatively high levels of these enzymes contribute to the reduction of DCPIP in the DTD assay, as was noticed in normal liver. In these samples, total reductase activity on DCPIP could be inhibited only by 50% by dicoumarol. Although no correlation between the levels of these enzymes (measured under aerobic conditions) and E09 cytotoxicity in cell lines was found, it is conceivable that these enzymes play a role in the hypoxic part of the tumour (Plumb et al., 1994a,c) . However, the small differences among the several tissue types rule out a possible role as predictive marker for these enzymes.
The potency of E09 under hypoxic conditions makes it an interesting compound to combine with radiation. Since encouraging results have been found in preclinical studies using cell lines and rats, clinical trials with this combination should be considered Kal et al., 1994; Stratford et al., 1994) .
Correlations between E09 sensitivity and DTD activity in vivo are limited to only a few murine models Walton et al., 1992) and rat (Kal et al., 1994) . Although the relation was positively similar to that found in in vitro studies, DTD levels in patients entering clinical trials should be measured since these levels are expected to have predictive value. High DTD levels would be associated with a response to E09. This is in line with the theory of enzyme profiling before determining therapy, as suggested by Riley and Workman 1992; Walton et al., 1992b) .
In conclusion, based on these observations in human tumours (absolute activity and relative to normal tissue), patients with NSCLC and those with colon tumours are more likely to be sensitive to E09 than those with squamous cell carcinoma of head and neck. This should be validated by measuring DTD levels in patients undergoing E09 treatment, such as those participating in the clinical trials.
